Nicole Lamanna, MD, and Nirav N. Shah, MD, discuss the use of BTK inhibitors as targeted therapy for chronic lymphocytic leukemia and recent advancements.
EP. 1: Chronic Lymphocytic Leukemia Treatment Landscape
Nicole Lamanna, MD, and Nirav N. Shah, MD, discuss the chronic lymphocytic leukemia treatment (CLL) landscape, including risk factors and treatment options.
EP. 2: Covalent BTK Inhibitors and Common Challenges
Dr Lamanna introduces covalent BTK inhibitors and their use in patients with CLL
EP. 3: Challenges With BTK Inhibitors
Dr Lamanna explains the challenges associated with BTK inhibitors.
EP. 4: Challenges Continued
Nicole Lamanna, MD, continues her discussion on BTK inhibitor challenges.
EP. 5: Non-Covalent BTK Inhibitors
Dr Shah introduces non-covalent BTK inhibitors and clinical findings from their use in the CLL landscape.
EP. 6: Clinical Implications of BTK Inhibitors in CLL
Dr Shah explains the clinical implications of using BTK inhibitors for CLL treatment.
EP. 7: Clinical Implications Continued
Dr Lamanna expands on BTK clinical implications within CLL therapy.
EP. 8: BTK Inhibitors and Other B-Cell Malignancies
Two experts discuss the use of BTK inhibitors in the treatment of other B-cell malignancies.
EP. 9: Future Directions for BTK Inhibitors
Nicole Lamanna, MD, and Nirav N. Shah, MD, conclude with their thoughts on the future of BTK inhibitors in CLL.
Experts Weigh in on Topic of Frontline Osimertinib Alone or With Chemo in EGFR-Mutant NSCLC
Dr Sands on the Evolving Role of ADCs in SCLC Management
Dr Hirsch on the Treatment of NRG1 Fusion+ NSCLC
MRD Testing Requires Prospective Data to Assess Clinical Utility in Breast Cancer